Goryń Tomasz, Szostakowski Bartłomiej, Pieńkowski Andrzej, Zdzienicki Marcin, Ługowska Iwona, Rutkowski Piotr
Department of Soft Tissue/Bone Sarcoma and Melanoma, Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Contemp Oncol (Pozn). 2019;23(4):234-238. doi: 10.5114/wo.2019.89782. Epub 2019 Nov 25.
Osteosarcoma is the most common primary malignant bone tumor in adults and is usually located in long bones. Standard treatment consists of perioperative chemotherapy and radical surgical resection. In the case of the extremity location, the gold standard is limb-sparing surgery (LSS) using a variety of reconstructive techniques.
To assess long-term results of adults patients treated for limb osteosarcoma in our referral center depending on the method of surgical treatment.
In our study, we analyzed 175 adult patients with localized disease (American Joint Committee on Cancer [AJCC] stage I-III) treated for extremity osteosarcoma at our institution between 2000 and 2017. The median observation time was 41 months (3-225 months). 111 patients were treated with LSS (80 patients had tumor resection followed by endoprosthetic reconstruction, 31 patients had local resection without reconstruction) and 64 patients underwent amputation.
5-year overall survival (OS) and progression-free survival (PFS) in the study group were 62% and 52% and the life expectancy was on average 136 months. In the group of patients treated with LSS, 5-year OS and PFS were 66% and 59%, respectively, and life expectancy was 147 months, while in the group of patients undergoing amputation 5-year OS, PFS and life expectancy were 55%, 42% and 117 months.
The best results in the treatment of extremity osteosarcoma were achieved in a group of patients without distant metastases at the time of diagnosis, treated with perioperative chemotherapy and radical resection followed by endoprosthetic reconstruction.
骨肉瘤是成人中最常见的原发性恶性骨肿瘤,通常位于长骨。标准治疗包括围手术期化疗和根治性手术切除。对于肢体部位的骨肉瘤,金标准是采用多种重建技术的保肢手术(LSS)。
评估在我们的转诊中心接受肢体骨肉瘤治疗的成年患者根据手术治疗方法的长期结果。
在我们的研究中,我们分析了2000年至2017年间在我们机构接受肢体骨肉瘤治疗的175例局限性疾病(美国癌症联合委员会[AJCC] I - III期)成年患者。中位观察时间为41个月(3 - 225个月)。111例患者接受了保肢手术(80例患者进行肿瘤切除后行假体置换重建,31例患者进行局部切除未行重建),64例患者接受了截肢手术。
研究组的5年总生存率(OS)和无进展生存率(PFS)分别为62%和52%,平均预期寿命为136个月。在接受保肢手术的患者组中,5年OS和PFS分别为66%和59%,预期寿命为147个月,而在接受截肢手术的患者组中,5年OS、PFS和预期寿命分别为55%、42%和117个月。
对于肢体骨肉瘤的治疗,在诊断时无远处转移、接受围手术期化疗和根治性切除后行假体置换重建的患者组中取得了最佳结果。